Loading
The published plan for PATHFINDER, the first study to give Galleri results back to people without symptoms, set out what it would measure and what it expected to find.
Design paper for PATHFINDER (NCT04241796): about 6,200 participants aged 50 or older with or without additional cancer risk factors would have a targeted methylation cell-free DNA test, with signal-detected participants evaluated at their physician's discretion. The primary objective was the number and types of diagnostic tests needed for diagnostic resolution. From microsimulations the authors expected a median of 106 signal-detected results, 52 cancers and a positive predictive value of 49% (95% CI 39 to 58).
Set beside the result (35 cancers among 92 positives, positive predictive value 38%), it shows the test found fewer cancers than its makers had modelled.
Shares GRAIL, Positive predictive value (PPV), Galleri, Multi-cancer early detection (MCED).
Shares GRAIL, Positive predictive value (PPV), Galleri, Multi-cancer early detection (MCED).
Shares PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms, GRAIL, Positive predictive value (PPV), Galleri.
Shares GRAIL, Positive predictive value (PPV), Galleri, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/